PTEN mutations have been found in 4�8% of all NSCLC and more commonly in smokers and in tumors with squamous cell histology. Somatic mutations of PTEN have been reported in multiple malignancies, including gliomas, melanoma, prostate, endometrial, breast, ovarian, renal, and lung cancers (Lovly, C., L. Horn, W. Pao. 2015. PTEN in Non-Small Cell Lung Cancer (NSCLC). My Cancer Genome https://www.mycancergenome.org/content/disease/lung-cancer/pten/ (Updated June 18).). Identification of PTEN mutations can significantly affect the management of lung cancer patients by allowing them an opportunity to be enrolled in open clinical trials (https://clinicaltrials.gov/show/NCT01884285).